# Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

> **NCT01691339** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 200 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation
- **BIOLOGICAL:** Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation
- **BIOLOGICAL:** Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation
- **BIOLOGICAL:** Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation

## Key facts

- **NCT ID:** NCT01691339
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-11
- **Final completion:** 2013-02
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2013-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691339, "Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01691339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*